Hep Free NYC supports the Immunization Action Coalition's National Hep B Birth Dose Honor Roll initiative. NYC Hep B Universal Birth Dose Initiative aims to gather support for the hepatitis B birth dose in New York City.
General News
As New York State enters this era of successful HCV treatment, the NYSDOH AIDS Institute has developed criteria for defining those providers qualified to manage and treat patients with HCV infection.
President Obama has proposed to double funding for DVH (for a total of $62.8 million).
Bringing awareness of Hepatic disease to Russian community.
Tour Notes:Callen-Lorde Community Health Center Hep C Program June 16th, 2015 (3-5 PM) – 356 W 18th St, New York, NY 10011 NYC Hepatitis Patient Navigator Network Leader: Paul Bolter – PBolter@liverfoundation.org To Join our Hep Free NYC Patient Navigator Network and ...
This Plan updates the Center’s current strategic plan and serves as a blueprint for achieving our vision of a future free of HIV, viral hepatitis, STDs, and TB.
Hepatitis C Provider Survey HealthHCV, an advocacy and education initiative of HealthHIV, is launching its inaugural State of HCV Care national survey in partnership with Medscape. This survey will reach providers nationwide, specifically hepatologists, gastroenterologists, infe...
YSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
On Feb 26th, 2015, the NYS Drug Utilization Review Board (DURB) voted unanimously to move Viekira Pak to preferred status for NYS Medicaid Fee-for-service members, and to remove restrictions based on disease prognosis and severity from the current clinical criteria for Viekira Pa...
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
